| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 109 | 2025 | 622 | 21.690 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 53 | 2025 | 1188 | 7.400 |
Why?
|
| Bone Marrow Transplantation | 49 | 2023 | 620 | 6.660 |
Why?
|
| T-Lymphocytes | 32 | 2024 | 1814 | 5.170 |
Why?
|
| Dendritic Cells | 20 | 2019 | 447 | 4.310 |
Why?
|
| Transplantation, Homologous | 62 | 2024 | 692 | 4.170 |
Why?
|
| Histone Deacetylase Inhibitors | 9 | 2017 | 92 | 2.730 |
Why?
|
| Gastrointestinal Microbiome | 10 | 2025 | 823 | 2.480 |
Why?
|
| Intestines | 9 | 2025 | 614 | 2.330 |
Why?
|
| Transplantation Conditioning | 17 | 2024 | 300 | 2.330 |
Why?
|
| Graft vs Leukemia Effect | 8 | 2020 | 36 | 2.210 |
Why?
|
| Mice, Inbred BALB C | 29 | 2024 | 1079 | 2.150 |
Why?
|
| Mice, Inbred C57BL | 45 | 2025 | 4822 | 2.020 |
Why?
|
| MicroRNAs | 8 | 2019 | 950 | 1.910 |
Why?
|
| Mice | 72 | 2025 | 18910 | 1.850 |
Why?
|
| Animals | 93 | 2025 | 36377 | 1.830 |
Why?
|
| Inflammation | 11 | 2025 | 1590 | 1.810 |
Why?
|
| Hydroxamic Acids | 5 | 2017 | 65 | 1.720 |
Why?
|
| Hematologic Neoplasms | 8 | 2024 | 294 | 1.700 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2016 | 247 | 1.670 |
Why?
|
| Colitis | 4 | 2021 | 173 | 1.660 |
Why?
|
| Fatty Acids, Volatile | 4 | 2020 | 47 | 1.530 |
Why?
|
| Cytokines | 18 | 2020 | 1393 | 1.470 |
Why?
|
| Antigen-Presenting Cells | 11 | 2014 | 133 | 1.430 |
Why?
|
| STAT3 Transcription Factor | 5 | 2017 | 230 | 1.370 |
Why?
|
| RNA, Long Noncoding | 3 | 2022 | 246 | 1.310 |
Why?
|
| Stem Cells | 2 | 2025 | 753 | 1.300 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2021 | 568 | 1.300 |
Why?
|
| Acute Disease | 32 | 2020 | 1190 | 1.290 |
Why?
|
| Metabolome | 3 | 2025 | 312 | 1.220 |
Why?
|
| R-SNARE Proteins | 2 | 2019 | 11 | 1.200 |
Why?
|
| Graft vs Tumor Effect | 3 | 2020 | 9 | 1.200 |
Why?
|
| Autoimmunity | 2 | 2021 | 181 | 1.130 |
Why?
|
| Isoantigens | 7 | 2018 | 25 | 1.120 |
Why?
|
| Interleukin-10 | 3 | 2016 | 191 | 1.110 |
Why?
|
| Epithelial Cells | 4 | 2024 | 935 | 1.060 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2016 | 382 | 1.060 |
Why?
|
| Interleukin-6 | 4 | 2015 | 449 | 1.050 |
Why?
|
| Mitochondria | 3 | 2021 | 744 | 1.040 |
Why?
|
| Interleukin-18 | 5 | 2004 | 68 | 1.040 |
Why?
|
| Immune Tolerance | 2 | 2017 | 158 | 1.000 |
Why?
|
| Mice, Knockout | 18 | 2021 | 3981 | 0.980 |
Why?
|
| Tacrolimus | 3 | 2017 | 107 | 0.950 |
Why?
|
| Hematologic Diseases | 2 | 2025 | 82 | 0.930 |
Why?
|
| alpha 1-Antitrypsin | 2 | 2018 | 85 | 0.930 |
Why?
|
| CD8 Antigens | 4 | 2015 | 45 | 0.900 |
Why?
|
| T-Lymphocyte Subsets | 8 | 2014 | 215 | 0.880 |
Why?
|
| Immunosuppressive Agents | 7 | 2015 | 692 | 0.880 |
Why?
|
| Immunologic Memory | 1 | 2025 | 199 | 0.870 |
Why?
|
| Gene Expression Regulation | 10 | 2022 | 2651 | 0.870 |
Why?
|
| Oxidative Phosphorylation | 3 | 2021 | 128 | 0.850 |
Why?
|
| Antigen Presentation | 5 | 2017 | 117 | 0.840 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 4 | 2014 | 21 | 0.810 |
Why?
|
| Endoplasmic Reticulum | 2 | 2021 | 228 | 0.800 |
Why?
|
| Lymphocyte Activation | 13 | 2020 | 724 | 0.780 |
Why?
|
| Humans | 94 | 2025 | 133390 | 0.780 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 773 | 0.780 |
Why?
|
| Cells, Cultured | 12 | 2021 | 3168 | 0.780 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2021 | 277 | 0.770 |
Why?
|
| Colon | 3 | 2021 | 378 | 0.760 |
Why?
|
| Electron Transport Complex II | 1 | 2021 | 2 | 0.760 |
Why?
|
| Bacteria | 2 | 2019 | 533 | 0.750 |
Why?
|
| Immunity, Cellular | 5 | 2017 | 217 | 0.750 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 148 | 0.750 |
Why?
|
| Immune System Diseases | 1 | 2022 | 49 | 0.750 |
Why?
|
| Female | 71 | 2025 | 71455 | 0.720 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 361 | 0.710 |
Why?
|
| Histone Deacetylases | 4 | 2016 | 122 | 0.710 |
Why?
|
| COP-Coated Vesicles | 1 | 2021 | 5 | 0.710 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2020 | 15 | 0.710 |
Why?
|
| Disease Models, Animal | 19 | 2024 | 4778 | 0.690 |
Why?
|
| Golgi Apparatus | 1 | 2021 | 96 | 0.690 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2024 | 315 | 0.680 |
Why?
|
| Hematology | 1 | 2020 | 42 | 0.680 |
Why?
|
| Methotrexate | 2 | 2024 | 355 | 0.650 |
Why?
|
| Hematopoietic System | 1 | 2019 | 7 | 0.650 |
Why?
|
| Lipopolysaccharides | 6 | 2019 | 320 | 0.650 |
Why?
|
| Cell Differentiation | 6 | 2024 | 2025 | 0.640 |
Why?
|
| Mice, Inbred C3H | 6 | 2019 | 122 | 0.640 |
Why?
|
| Th2 Cells | 3 | 2011 | 191 | 0.630 |
Why?
|
| Sirtuin 3 | 1 | 2018 | 10 | 0.610 |
Why?
|
| Receptors, Cell Surface | 2 | 2019 | 497 | 0.610 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 888 | 0.590 |
Why?
|
| Unrelated Donors | 2 | 2018 | 70 | 0.580 |
Why?
|
| Signal Transduction | 11 | 2019 | 4897 | 0.580 |
Why?
|
| Histocompatibility | 3 | 2021 | 50 | 0.570 |
Why?
|
| Endothelial Cells | 2 | 2019 | 543 | 0.560 |
Why?
|
| RNA, Untranslated | 1 | 2018 | 120 | 0.560 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2018 | 445 | 0.550 |
Why?
|
| Embryonic Development | 1 | 2019 | 222 | 0.550 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 125 | 0.550 |
Why?
|
| Steroids | 1 | 2018 | 210 | 0.550 |
Why?
|
| Intestinal Mucosa | 2 | 2021 | 815 | 0.540 |
Why?
|
| Allografts | 10 | 2019 | 198 | 0.540 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2016 | 3 | 0.540 |
Why?
|
| Myeloid Cells | 1 | 2017 | 123 | 0.520 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 503 | 0.510 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 407 | 0.500 |
Why?
|
| Peer Review, Research | 1 | 2016 | 46 | 0.490 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2018 | 522 | 0.490 |
Why?
|
| Butyrates | 3 | 2023 | 42 | 0.480 |
Why?
|
| Transplantation Immunology | 3 | 2016 | 56 | 0.480 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2025 | 563 | 0.480 |
Why?
|
| Survival Rate | 16 | 2019 | 2210 | 0.470 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 34 | 0.470 |
Why?
|
| Models, Biological | 2 | 2018 | 1532 | 0.460 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2017 | 214 | 0.460 |
Why?
|
| Immunotherapy | 2 | 2017 | 746 | 0.460 |
Why?
|
| Trans-Activators | 2 | 2013 | 830 | 0.450 |
Why?
|
| Biomarkers | 13 | 2019 | 3424 | 0.450 |
Why?
|
| Busulfan | 3 | 2015 | 45 | 0.450 |
Why?
|
| Boronic Acids | 1 | 2014 | 48 | 0.450 |
Why?
|
| Receptor, Notch1 | 2 | 2013 | 79 | 0.450 |
Why?
|
| Dysbiosis | 3 | 2025 | 145 | 0.450 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2013 | 506 | 0.440 |
Why?
|
| CD24 Antigen | 1 | 2014 | 32 | 0.440 |
Why?
|
| Acetylation | 4 | 2017 | 183 | 0.440 |
Why?
|
| Immune System | 3 | 2022 | 98 | 0.440 |
Why?
|
| Lectins | 1 | 2014 | 57 | 0.440 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2014 | 33 | 0.440 |
Why?
|
| Pyrazines | 1 | 2014 | 73 | 0.440 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 150 | 0.430 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2014 | 46 | 0.430 |
Why?
|
| Mycophenolic Acid | 1 | 2013 | 52 | 0.420 |
Why?
|
| Carrier Proteins | 2 | 2016 | 1066 | 0.420 |
Why?
|
| Ubiquitins | 1 | 2013 | 45 | 0.420 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2019 | 30 | 0.420 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2019 | 1070 | 0.410 |
Why?
|
| Leukemia | 5 | 2013 | 380 | 0.400 |
Why?
|
| Adult | 31 | 2025 | 31786 | 0.400 |
Why?
|
| Hematopoiesis | 2 | 2011 | 230 | 0.400 |
Why?
|
| Flow Cytometry | 5 | 2019 | 836 | 0.400 |
Why?
|
| Models, Animal | 3 | 2018 | 483 | 0.390 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 2526 | 0.380 |
Why?
|
| H-Y Antigen | 1 | 2011 | 1 | 0.380 |
Why?
|
| Leukocyte Transfusion | 1 | 2011 | 7 | 0.380 |
Why?
|
| Middle Aged | 33 | 2025 | 29208 | 0.380 |
Why?
|
| Tissue Donors | 6 | 2018 | 523 | 0.380 |
Why?
|
| Pancreatitis-Associated Proteins | 5 | 2018 | 15 | 0.370 |
Why?
|
| Basophils | 1 | 2011 | 13 | 0.370 |
Why?
|
| Adaptation, Physiological | 1 | 2013 | 288 | 0.360 |
Why?
|
| Recurrence | 6 | 2021 | 1464 | 0.360 |
Why?
|
| Ikaros Transcription Factor | 1 | 2011 | 32 | 0.360 |
Why?
|
| Cell Proliferation | 7 | 2021 | 2548 | 0.350 |
Why?
|
| Inflammation Mediators | 3 | 2013 | 258 | 0.350 |
Why?
|
| Toll-Like Receptor 4 | 3 | 2019 | 145 | 0.350 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 5 | 2017 | 54 | 0.350 |
Why?
|
| Microbiota | 3 | 2025 | 443 | 0.340 |
Why?
|
| Immunity, Innate | 3 | 2019 | 416 | 0.340 |
Why?
|
| Male | 39 | 2025 | 65685 | 0.330 |
Why?
|
| Graft Survival | 4 | 2014 | 557 | 0.320 |
Why?
|
| Apoptosis | 6 | 2018 | 1928 | 0.320 |
Why?
|
| Hepatitis B | 1 | 2011 | 173 | 0.320 |
Why?
|
| Survival Analysis | 6 | 2017 | 1596 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 616 | 0.310 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 3 | 2018 | 21 | 0.310 |
Why?
|
| Cell Communication | 3 | 2021 | 186 | 0.310 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 607 | 0.300 |
Why?
|
| Sepsis | 2 | 2011 | 517 | 0.300 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1334 | 0.290 |
Why?
|
| Kidney Transplantation | 2 | 2011 | 689 | 0.290 |
Why?
|
| Histones | 3 | 2017 | 568 | 0.290 |
Why?
|
| Aged | 22 | 2020 | 21605 | 0.280 |
Why?
|
| Feasibility Studies | 2 | 2023 | 814 | 0.280 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 19 | 0.280 |
Why?
|
| Semaphorins | 1 | 2007 | 33 | 0.280 |
Why?
|
| Feces | 3 | 2024 | 788 | 0.280 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 1755 | 0.280 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 971 | 0.270 |
Why?
|
| Interleukins | 1 | 2008 | 130 | 0.270 |
Why?
|
| RNA, Messenger | 1 | 2013 | 2899 | 0.270 |
Why?
|
| Immunoglobulin G | 4 | 2014 | 824 | 0.270 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1850 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2014 | 79 | 0.270 |
Why?
|
| Lymphopenia | 1 | 2007 | 39 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2509 | 0.260 |
Why?
|
| Up-Regulation | 3 | 2015 | 905 | 0.260 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 1918 | 0.260 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 866 | 0.250 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2018 | 149 | 0.240 |
Why?
|
| Gene Expression | 4 | 2016 | 1614 | 0.240 |
Why?
|
| Stomatitis | 1 | 2025 | 17 | 0.240 |
Why?
|
| Photochemotherapy | 1 | 2005 | 44 | 0.230 |
Why?
|
| Cyclopentanes | 2 | 2016 | 22 | 0.230 |
Why?
|
| Multiple Myeloma | 2 | 2019 | 201 | 0.230 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2018 | 388 | 0.230 |
Why?
|
| Transcription Factors | 1 | 2015 | 2704 | 0.230 |
Why?
|
| Immunophenotyping | 2 | 2018 | 342 | 0.220 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2018 | 45 | 0.220 |
Why?
|
| Bacteroides | 1 | 2024 | 37 | 0.220 |
Why?
|
| Mouth | 1 | 2025 | 71 | 0.220 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2017 | 36 | 0.220 |
Why?
|
| Lymphocyte Depletion | 2 | 2019 | 125 | 0.220 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2018 | 39 | 0.220 |
Why?
|
| Homeostasis | 2 | 2019 | 745 | 0.220 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 432 | 0.220 |
Why?
|
| Th1 Cells | 1 | 2004 | 159 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 168 | 0.210 |
Why?
|
| Genomic Imprinting | 1 | 2024 | 129 | 0.210 |
Why?
|
| B-Lymphocytes | 4 | 2016 | 550 | 0.210 |
Why?
|
| Regeneration | 2 | 2024 | 231 | 0.210 |
Why?
|
| Peroxidase | 2 | 2020 | 72 | 0.210 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 38 | 0.210 |
Why?
|
| Etanercept | 5 | 2015 | 47 | 0.210 |
Why?
|
| NF-kappa B | 3 | 2015 | 480 | 0.210 |
Why?
|
| Organ Specificity | 3 | 2017 | 444 | 0.200 |
Why?
|
| Mastocytoma | 1 | 2002 | 1 | 0.200 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 94 | 0.200 |
Why?
|
| HLA Antigens | 3 | 2016 | 253 | 0.200 |
Why?
|
| Chronic Disease | 6 | 2025 | 1252 | 0.200 |
Why?
|
| Photopheresis | 2 | 2015 | 5 | 0.200 |
Why?
|
| Adolescent | 20 | 2020 | 20505 | 0.200 |
Why?
|
| Quinone Reductases | 1 | 2021 | 4 | 0.190 |
Why?
|
| Hydrogen Sulfide | 1 | 2021 | 15 | 0.190 |
Why?
|
| Succinic Acid | 1 | 2021 | 15 | 0.190 |
Why?
|
| Pyrimidines | 2 | 2016 | 417 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 255 | 0.180 |
Why?
|
| Lectins, C-Type | 2 | 2012 | 75 | 0.180 |
Why?
|
| Prospective Studies | 7 | 2018 | 6570 | 0.180 |
Why?
|
| Paneth Cells | 2 | 2018 | 26 | 0.180 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 94 | 0.180 |
Why?
|
| Histocompatibility Testing | 4 | 2016 | 151 | 0.180 |
Why?
|
| Organoids | 1 | 2024 | 298 | 0.180 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 204 | 0.180 |
Why?
|
| Protein Binding | 2 | 2016 | 1832 | 0.180 |
Why?
|
| Biological Transport, Active | 1 | 2021 | 89 | 0.180 |
Why?
|
| Neutropenia | 1 | 2022 | 201 | 0.180 |
Why?
|
| Mammals | 1 | 2022 | 277 | 0.170 |
Why?
|
| Erythropoiesis | 1 | 2020 | 43 | 0.170 |
Why?
|
| Mice, Mutant Strains | 2 | 2011 | 400 | 0.170 |
Why?
|
| Young Adult | 10 | 2020 | 9852 | 0.170 |
Why?
|
| Cell Line | 3 | 2019 | 2836 | 0.170 |
Why?
|
| Spleen | 3 | 2019 | 291 | 0.170 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 1326 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 380 | 0.170 |
Why?
|
| Interferon-alpha | 1 | 2021 | 248 | 0.160 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2010 | 90 | 0.160 |
Why?
|
| Erythropoietin | 1 | 2020 | 110 | 0.160 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 3082 | 0.160 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2019 | 27 | 0.160 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2019 | 37 | 0.160 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2019 | 61 | 0.160 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 21 | 0.160 |
Why?
|
| Antigens, Neoplasm | 2 | 2012 | 407 | 0.150 |
Why?
|
| Endotoxins | 1 | 2019 | 50 | 0.150 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2018 | 16 | 0.150 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 34 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 335 | 0.150 |
Why?
|
| Stem Cell Transplantation | 2 | 2015 | 250 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2014 | 401 | 0.150 |
Why?
|
| Glycolysis | 1 | 2019 | 170 | 0.150 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 9 | 0.150 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2018 | 35 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 132 | 0.140 |
Why?
|
| Interferon-gamma | 7 | 2015 | 538 | 0.140 |
Why?
|
| NIH 3T3 Cells | 2 | 2019 | 96 | 0.140 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2024 | 170 | 0.140 |
Why?
|
| Macrophages | 2 | 2020 | 703 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 2020 | 1603 | 0.140 |
Why?
|
| Cross-Priming | 1 | 2017 | 5 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 440 | 0.140 |
Why?
|
| Mice, Inbred DBA | 2 | 2010 | 56 | 0.140 |
Why?
|
| Primary Cell Culture | 2 | 2018 | 110 | 0.140 |
Why?
|
| Cellular Microenvironment | 1 | 2017 | 9 | 0.140 |
Why?
|
| Risk Factors | 10 | 2017 | 11085 | 0.140 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 273 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 162 | 0.140 |
Why?
|
| Interleukin-15 | 1 | 2018 | 96 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2018 | 264 | 0.140 |
Why?
|
| Physicians | 1 | 2024 | 631 | 0.140 |
Why?
|
| Models, Immunological | 1 | 2017 | 38 | 0.140 |
Why?
|
| Embryo, Mammalian | 1 | 2019 | 464 | 0.140 |
Why?
|
| Protein Transport | 2 | 2020 | 386 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1313 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 167 | 0.130 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 125 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 405 | 0.130 |
Why?
|
| Incidence | 2 | 2017 | 3396 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 247 | 0.130 |
Why?
|
| Inflammasomes | 1 | 2018 | 165 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2019 | 370 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 97 | 0.130 |
Why?
|
| RNA Interference | 1 | 2018 | 543 | 0.130 |
Why?
|
| Methylprednisolone | 2 | 2007 | 102 | 0.130 |
Why?
|
| Neutrophils | 1 | 2018 | 400 | 0.130 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 85 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 1068 | 0.130 |
Why?
|
| Microarray Analysis | 1 | 2016 | 238 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 696 | 0.120 |
Why?
|
| E2F7 Transcription Factor | 1 | 2015 | 1 | 0.120 |
Why?
|
| Ubiquitination | 1 | 2016 | 183 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2016 | 317 | 0.120 |
Why?
|
| Chemokines | 1 | 2016 | 138 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2018 | 341 | 0.120 |
Why?
|
| United States | 4 | 2024 | 11677 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2013 | 212 | 0.120 |
Why?
|
| Transplantation, Autologous | 1 | 2016 | 285 | 0.120 |
Why?
|
| Transplant Recipients | 1 | 2017 | 225 | 0.120 |
Why?
|
| Stomach Diseases | 1 | 2015 | 57 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1626 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2013 | 644 | 0.120 |
Why?
|
| Vidarabine | 1 | 2015 | 78 | 0.120 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 317 | 0.120 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2014 | 29 | 0.120 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 87 | 0.110 |
Why?
|
| Leukocyte Common Antigens | 1 | 2014 | 93 | 0.110 |
Why?
|
| Leukemia, Experimental | 2 | 2005 | 17 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 551 | 0.110 |
Why?
|
| Radiation | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2015 | 148 | 0.110 |
Why?
|
| Bortezomib | 1 | 2014 | 72 | 0.110 |
Why?
|
| Glucose | 1 | 2019 | 923 | 0.110 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 48 | 0.110 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Haplotypes | 1 | 2016 | 561 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 1 | 2014 | 31 | 0.110 |
Why?
|
| Acute Lung Injury | 1 | 2015 | 68 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2015 | 130 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3642 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 327 | 0.110 |
Why?
|
| Argonaute Proteins | 1 | 2013 | 31 | 0.110 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 991 | 0.110 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2013 | 4 | 0.110 |
Why?
|
| NEDD8 Protein | 1 | 2013 | 12 | 0.110 |
Why?
|
| Thymectomy | 2 | 2011 | 25 | 0.110 |
Why?
|
| Genome | 1 | 2016 | 526 | 0.110 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 1153 | 0.110 |
Why?
|
| I-kappa B Proteins | 1 | 2013 | 42 | 0.110 |
Why?
|
| Receptor, Notch2 | 1 | 2013 | 12 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 67 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 358 | 0.100 |
Why?
|
| DNA | 1 | 2019 | 1674 | 0.100 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2013 | 109 | 0.100 |
Why?
|
| Cognition | 1 | 2018 | 816 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2012 | 1717 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 1787 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2015 | 626 | 0.100 |
Why?
|
| Child, Preschool | 12 | 2018 | 14788 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2012 | 38 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2013 | 3696 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2020 | 999 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 395 | 0.100 |
Why?
|
| Proteolysis | 1 | 2013 | 193 | 0.100 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2011 | 53 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 793 | 0.090 |
Why?
|
| Lymphoma | 2 | 2013 | 335 | 0.090 |
Why?
|
| Infant | 11 | 2018 | 13158 | 0.090 |
Why?
|
| Adenine Nucleotides | 1 | 2011 | 41 | 0.090 |
Why?
|
| Arabinonucleosides | 1 | 2011 | 33 | 0.090 |
Why?
|
| Patient Participation | 1 | 2014 | 236 | 0.090 |
Why?
|
| Retrospective Studies | 10 | 2019 | 17378 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2011 | 54 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 214 | 0.090 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 959 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2011 | 77 | 0.090 |
Why?
|
| Remission Induction | 3 | 2019 | 307 | 0.090 |
Why?
|
| Mice, 129 Strain | 1 | 2010 | 99 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2013 | 717 | 0.090 |
Why?
|
| Transplantation Chimera | 3 | 2005 | 44 | 0.090 |
Why?
|
| Mice, Inbred Strains | 2 | 2008 | 321 | 0.090 |
Why?
|
| Liver Failure | 1 | 2011 | 91 | 0.080 |
Why?
|
| 3' Untranslated Regions | 1 | 2011 | 182 | 0.080 |
Why?
|
| Time Factors | 4 | 2019 | 6569 | 0.080 |
Why?
|
| Elafin | 1 | 2010 | 2 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2015 | 869 | 0.080 |
Why?
|
| Pancreas Transplantation | 1 | 2010 | 39 | 0.080 |
Why?
|
| Cell Separation | 1 | 2010 | 234 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 604 | 0.080 |
Why?
|
| Child | 13 | 2020 | 25733 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2014 | 733 | 0.080 |
Why?
|
| Drugs, Investigational | 1 | 2009 | 24 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 2009 | 128 | 0.080 |
Why?
|
| Radiation Chimera | 3 | 2003 | 18 | 0.080 |
Why?
|
| Autografts | 2 | 2019 | 29 | 0.080 |
Why?
|
| Skin | 2 | 2010 | 548 | 0.080 |
Why?
|
| Graft vs Host Reaction | 1 | 2008 | 11 | 0.070 |
Why?
|
| Immunologic Tests | 1 | 2008 | 20 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2018 | 12971 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2008 | 57 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1139 | 0.070 |
Why?
|
| Proteins | 1 | 2013 | 1087 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 247 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 894 | 0.070 |
Why?
|
| Interleukin-8 | 1 | 2008 | 221 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 3024 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1161 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2020 | 813 | 0.070 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2007 | 34 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2014 | 1145 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 1484 | 0.070 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2004 | 113 | 0.070 |
Why?
|
| Lung | 1 | 2015 | 1557 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2009 | 1134 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2009 | 315 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2005 | 702 | 0.070 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2004 | 19 | 0.060 |
Why?
|
| Perforin | 2 | 2004 | 26 | 0.060 |
Why?
|
| Prognosis | 5 | 2018 | 5074 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2008 | 452 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 714 | 0.060 |
Why?
|
| Phenotype | 2 | 2013 | 4551 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2007 | 613 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2011 | 824 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 317 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2005 | 33 | 0.060 |
Why?
|
| Bacteroides thetaiotaomicron | 1 | 2024 | 9 | 0.060 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2004 | 1 | 0.060 |
Why?
|
| Interleukin-18 Receptor alpha Subunit | 1 | 2004 | 2 | 0.060 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 36 | 0.060 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 801 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 224 | 0.050 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 49 | 0.050 |
Why?
|
| Ontario | 1 | 2023 | 91 | 0.050 |
Why?
|
| Clonal Deletion | 1 | 2003 | 3 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2024 | 158 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3751 | 0.050 |
Why?
|
| Liver | 3 | 2012 | 1876 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2022 | 15 | 0.050 |
Why?
|
| H-2 Antigens | 1 | 2002 | 26 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2003 | 105 | 0.050 |
Why?
|
| Propionates | 1 | 2022 | 33 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 39 | 0.050 |
Why?
|
| STAT6 Transcription Factor | 1 | 2002 | 38 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 77 | 0.050 |
Why?
|
| Career Choice | 1 | 2024 | 161 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 1193 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 134 | 0.050 |
Why?
|
| Electron Transport Complex IV | 1 | 2021 | 41 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 399 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2023 | 244 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 259 | 0.050 |
Why?
|
| Dextran Sulfate | 1 | 2021 | 51 | 0.050 |
Why?
|
| Epithelium | 1 | 2002 | 366 | 0.050 |
Why?
|
| Mutation | 1 | 2015 | 6290 | 0.040 |
Why?
|
| Quality of Life | 2 | 2023 | 2137 | 0.040 |
Why?
|
| Algorithms | 2 | 2019 | 1729 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 867 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 2020 | 44 | 0.040 |
Why?
|
| Killer Cells, Natural | 2 | 2019 | 357 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 465 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2021 | 140 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2003 | 276 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 138 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2002 | 391 | 0.040 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Muromegalovirus | 1 | 2019 | 11 | 0.040 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2019 | 25 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 776 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2017 | 8586 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2020 | 180 | 0.040 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 242 | 0.040 |
Why?
|
| Body Temperature | 1 | 2019 | 130 | 0.040 |
Why?
|
| Probability | 1 | 2019 | 335 | 0.040 |
Why?
|
| Leukocyte Elastase | 1 | 2018 | 22 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 1437 | 0.040 |
Why?
|
| Obesity | 1 | 2010 | 2411 | 0.040 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 38 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2010 | 3155 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2020 | 292 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 456 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 737 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2018 | 187 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 485 | 0.030 |
Why?
|
| Cellular Reprogramming | 1 | 2018 | 135 | 0.030 |
Why?
|
| Cell Survival | 1 | 2018 | 888 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 53 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1189 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3733 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 114 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2009 | 202 | 0.030 |
Why?
|
| Aging | 1 | 2002 | 1297 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2011 | 2294 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2015 | 101 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 3975 | 0.030 |
Why?
|
| Dibenzazepines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Focus Groups | 1 | 2014 | 211 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2018 | 1001 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2013 | 62 | 0.030 |
Why?
|
| Adoptive Transfer | 2 | 2005 | 241 | 0.030 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 9 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2013 | 250 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 2003 | 146 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2013 | 121 | 0.020 |
Why?
|
| Keratin-18 | 1 | 2012 | 7 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2012 | 61 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 176 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2013 | 336 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 382 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 294 | 0.020 |
Why?
|
| Informed Consent | 1 | 2014 | 345 | 0.020 |
Why?
|
| Syndrome | 1 | 2014 | 1158 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 332 | 0.020 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2011 | 26 | 0.020 |
Why?
|
| Lactates | 1 | 2011 | 97 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 341 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1671 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 755 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2011 | 110 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 589 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 608 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 314 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 2120 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5455 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 619 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2010 | 113 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2009 | 133 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 832 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1488 | 0.020 |
Why?
|
| Cause of Death | 1 | 2010 | 504 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 525 | 0.020 |
Why?
|
| Forecasting | 1 | 2009 | 376 | 0.020 |
Why?
|
| Proteomics | 1 | 2011 | 595 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2781 | 0.020 |
Why?
|
| Overweight | 1 | 2010 | 383 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3967 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 896 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2005 | 65 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 38 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 5175 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 2004 | 58 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2005 | 362 | 0.010 |
Why?
|
| Scleroderma, Diffuse | 1 | 2003 | 4 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2003 | 23 | 0.010 |
Why?
|
| Xerophthalmia | 1 | 2003 | 8 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2010 | 1709 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 40 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2003 | 63 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 2003 | 15 | 0.010 |
Why?
|
| Self Tolerance | 1 | 2003 | 6 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 292 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 83 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 2003 | 50 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2003 | 65 | 0.010 |
Why?
|
| Viscera | 1 | 2003 | 56 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 149 | 0.010 |
Why?
|
| Rituximab | 1 | 2003 | 164 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1349 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 246 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 1481 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 773 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2002 | 317 | 0.010 |
Why?
|
| Cell Movement | 1 | 2003 | 916 | 0.010 |
Why?
|